Alzheimer's disease is the leading cause of dementia and is expected to triple in prevalence by 2050, resulting in unsustainable healthcare costs. Treatments that delay diagnosis could reduce disease burden substantially, but primary prevention trials require large samples and extended durations. Secondary prevention trials enroll persons at increased risk for disease and may increase efficiency. This presentation will assess the ethical implications of Alzheimer's disease secondary prevention trial designs, especially as it relates to the disclosure of genetic and biomarker risk for Alzheimer's disease.
Speaker Biography - Joshua Grill, PhD,
Joshua Grill, PhD,
Associate Director, UCI Alzheimer’s Disease Research Center, UC Irvine, Director of Education, UCI Institute for Memory Impairm
Dr. Joshua Grill is an Associate Professor of Psychiatry and Human Behavior and Director of Education for the Institute for Memory Impairments and Neurological Disorders at the University of California, Irvine. He is the Associate Director of the UCI Alzheimer’s Disease Research Center and directs its Outreach, Recruitment, and Education Core.
Dr. Grill earned his doctorate in Neuroscience in the Department of Neurobiology and Anatomy at the Wake Forest University School of Medicine. He recently joined UCI after serving as the leader of the Recruitment and Education Core and the Director of the Katherine and Benjamin Kagan Alzheimer’s Disease Treatment Development Program within the Mary S. Easton Center for Alzheimer’s Disease Research at UCLA. Dr. Grill’s research is focused on the ethics and efficiency of clinical trials across the spectrum of Alzheimer’s disease.
Seminars are FREE and open to the public. If you can not attend, Videotapes of Public Health seminars are archived through the UC Irvine OpenCourseWare program - please visit OpenCourseWare: http://ocw.uci.edu.